Bioxcel Therapeutics, INC Form 4 insider transactions

Executive Vice President of BioXcel Therapeutics, Vincent O'Neill, reports the sale of common stock and vesting of restricted stock units according to a pre-arranged trading plan.

Chief Commercial Officer Matthew T. Wiley of BioXcel Therapeutics reports the acquisition and disposal of company stock and restricted stock units.

Matthew T. Wiley, Chief Commercial Officer of BioXcel Therapeutics, files an amended SEC Form 4/A to correct a previous filing regarding the disposition of Restricted Stock Units (RSUs).

Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Chief Commercial Officer Matthew T. Wiley of BioXcel Therapeutics, Inc. reports the vesting and sale of common stock and restricted stock units.

Richard Steinhart, CFO of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, reported the vesting of restricted stock units and subsequent sale of shares.

Executive Vice President of BioXcel Therapeutics, Vincent O'Neill, reports the acquisition and disposition of common stock and restricted stock units.

BioXcel Therapeutics CEO Vimal Mehta reports the conversion of Restricted Stock Units (RSUs) into common stock and subsequent sales of shares under a pre-arranged trading plan.

Vincent O'Neill, an executive at BioXcel Therapeutics, filed an amended SEC Form 4 to correct a previous report that incorrectly stated he was granted restricted stock units and options, clarifying he holds no such securities.

Director Michal Votruba reports the grant and immediate assignment of stock options to RSJ Investments SICAV a.s.

Director Sandeep Laumas acquired 17,000 stock options in BioXcel Therapeutics on June 10, 2024.

Director Peter Mueller acquired 17,000 stock options in BioXcel Therapeutics, Inc. on June 10, 2024.

Michael Patrick Miller, a director of BioXcel Therapeutics, acquired stock options exercisable for 17,000 shares of common stock.

Director June Bray acquired 17,000 stock options in BioXcel Therapeutics on June 10, 2024.

Vimal Mehta, CEO of BioXcel Therapeutics, reports multiple transactions involving the transfer and sale of common stock, including indirect holdings through BioXcel LLC and BioXcel Holdings, Inc.

Executive Vice President of BioXcel Therapeutics, Vincent O'Neill, reports the conversion of Restricted Stock Units (RSUs) into common stock and subsequent sale of shares, according to a Form 4 filing.

BioXcel Therapeutics CEO Vimal Mehta reported the sale of common stock and the vesting of restricted stock units (RSUs) in recent transactions.

Richard Steinhart, CFO of BioXcel Therapeutics, reports the sale of common stock and the vesting of restricted stock units (RSUs) in a recent SEC filing.

Matthew T. Wiley, Chief Commercial Officer of BioXcel Therapeutics, Inc., reports the acquisition and disposal of common stock and restricted stock units.

Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, reported the sale of common stock and the vesting of restricted stock units (RSUs) in recent transactions.

Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the sale of common stock and the vesting of restricted stock units.